Literature DB >> 7523541

Cytokeratins and tissue polypeptide antigen.

B E Sundström1, T I Stigbrand.   

Abstract

Cytokeratins (CKs), which are biochemically related to intermediate filaments (IFs), form an intracellular network of filaments that is believed to participate in maintaining the structural integrity of cells. Twenty individual polypeptides, divided into two groups, constitute the cytokeratin family. Each type of epithelial cell can be characterized by its content of cytokeratin polypeptides since the expression pattern varies with the type of epithelium. During transformation of normal epithelial cells into malignant cells, the cytokeratin patterns are usually maintained. This property has enabled the use of cytokerations as histological tumor markers, especially for tumors that are not easily classified. Cytokeratins 8, 18 and 19 are the most abundant cytokeratins in carcinomas. They are released into necrotic areas and can be found intratumorally and in blood, circulating as partially degraded complexes, and can as such be used as tumor markers. Cytokeratin deposits in tumors make these structures potential targets for radioimmunodetection and immunotherapy. The usefulness of tissue polypeptide antigen (TPA) as a serological tumor marker has been known for a long time. TPA is a molecular complex containing CK 8, 18 and 19 and determinations of TPA in serum samples can be used in the follow-up of patients with many types of cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523541     DOI: 10.1177/172460089400900207

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  11 in total

1.  Protein fragment domains identified using 2D gel electrophoresis/MALDI-TOF.

Authors:  Maria D Person; Jianjun Shen; Angelina Traner; Sean C Hensley; Herng-Hsiang Lo; James L Abbruzzese; Donghui Li
Journal:  J Biomol Tech       Date:  2006-04

Review 2.  Biomarker method validation in anticancer drug development.

Authors:  J Cummings; T H Ward; A Greystoke; M Ranson; C Dive
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

3.  Rapid diagnosis and follow up of bladder cancer patients using urinary high molecular weight cytokeratins.

Authors:  Abdelfattah M Attallah; Hanem A Sakr; Hisham Ismail; Mohamed F Ismail; Ashraf S Ibrahim; Mohamed M El-Sharabasy; Ibrahim El-Dosoky
Journal:  World J Urol       Date:  2006-05-17       Impact factor: 4.226

Review 4.  Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.

Authors:  Philip A J Crosbie; Rajesh Shah; Yvonne Summers; Caroline Dive; Fiona Blackhall
Journal:  Transl Lung Cancer Res       Date:  2013-10

5.  The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment.

Authors:  Yunfan Ma; Mengying Fan; Liang Dai; Xiaozheng Kang; Yiqiang Liu; Yu Sun; Wanpu Yan; Zhen Liang; Hongchao Xiong; Keneng Chen
Journal:  Tumour Biol       Date:  2015-05-16

Review 6.  Circulating tumour markers in breast cancer.

Authors:  Ettore Seregni; Antonio Coli; Nicola Mazzucca
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-04       Impact factor: 9.236

7.  Serum M3/M21 in ovarian cancer patients.

Authors:  C Tempfer; L Hefler; G Haeusler; G Sliutz; E Hanzal; A Reinthaller; C H Kainz
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  The effects of transurethral resection and cystoprostatectomy on dissemination of epithelial cells in the circulation of patients with bladder cancer.

Authors:  F Desgrandchamps; M Teren; L Dal Cortivo; J P Marolleau; P Bertheau; J M Villette; A Cortesse; P Teillac; A Le Duc; F C Hamdy
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

9.  Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.

Authors:  J Cummings; M Ranson; E Lacasse; J R Ganganagari; M St-Jean; G Jayson; J Durkin; C Dive
Journal:  Br J Cancer       Date:  2006-07-03       Impact factor: 7.640

10.  CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases.

Authors:  C Tempfer; L Hefler; H Heinzl; A Loesch; G Gitsch; H Rumpold; C Kainz
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.